Federal Register Notice: FDA is making available a draft guidance for industry, Suicidality: Prospective Assessment of Occurrence in Clinical Trials. Its purpose is to assist sponsors in prospectively assessing the occurrence of treatment-emergent suicidality in clinical trials of drug and biological products. It addresses the agency’s current thinking on the importance of suicidality assessment in psychiatric and nonpsychiatric drug trials and the general principles for how best to accomplish this assessment during drug development. To download this guidance, click here. To view this notice, click here.